Last reviewed · How we verify

Neurontin (Gabapentin)

Pfizer Inc. · FDA-approved approved Small molecule Verified Quality 79/100

Gabapentin binds with high-affinity to α2δ subunit of voltage-activated calcium channels; precise mechanism unknown.

Gabapentin is an antiepileptic and analgesic agent indicated for postherpetic neuralgia and adjunctive seizure management in adults and pediatric patients 3 years and older. It binds to α2δ subunits of voltage-activated calcium channels with high affinity, though the precise mechanism of therapeutic action remains unknown. Significant risk of respiratory depression and death exists with concurrent opioid use, requiring careful monitoring and potential dose adjustment. The drug is renally eliminated unchanged with a 5-7 hour half-life and shows non-dose-proportional bioavailability, necessitating individualized dosing particularly in elderly and renal-impaired patients.

At a glance

Generic nameGabapentin
SponsorPfizer Inc.
Drug classAntiepileptic/Analgesic
Targetα2δ subunit of voltage-activated calcium channels
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, or degradation. In vitro studies have shown that gabapentin binds with high-affinity to the α2δ subunit of voltage-activated calcium channels; however, the relationship of this binding to the therapeutic effects of gabapentin is unknown. The precise mechanisms by which gabapentin produces its analgesic and antiepileptic actions remain unknown.

Approved indications

Common side effects

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: